Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights

Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Starr, Jason S, Sonbol, Mohamad Bassam, Hobday, Timothy J, Sharma, Akash, Kendi, Ayse Tuba, Halfdanarson, Thorvardur R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205451/
https://www.ncbi.nlm.nih.gov/pubmed/32431509
http://dx.doi.org/10.2147/OTT.S202867
_version_ 1783530245010227200
author Starr, Jason S
Sonbol, Mohamad Bassam
Hobday, Timothy J
Sharma, Akash
Kendi, Ayse Tuba
Halfdanarson, Thorvardur R
author_facet Starr, Jason S
Sonbol, Mohamad Bassam
Hobday, Timothy J
Sharma, Akash
Kendi, Ayse Tuba
Halfdanarson, Thorvardur R
author_sort Starr, Jason S
collection PubMed
description Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.
format Online
Article
Text
id pubmed-7205451
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72054512020-05-19 Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights Starr, Jason S Sonbol, Mohamad Bassam Hobday, Timothy J Sharma, Akash Kendi, Ayse Tuba Halfdanarson, Thorvardur R Onco Targets Ther Review Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach. Dove 2020-04-28 /pmc/articles/PMC7205451/ /pubmed/32431509 http://dx.doi.org/10.2147/OTT.S202867 Text en © 2020 Starr et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Starr, Jason S
Sonbol, Mohamad Bassam
Hobday, Timothy J
Sharma, Akash
Kendi, Ayse Tuba
Halfdanarson, Thorvardur R
Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
title Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
title_full Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
title_fullStr Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
title_full_unstemmed Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
title_short Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
title_sort peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205451/
https://www.ncbi.nlm.nih.gov/pubmed/32431509
http://dx.doi.org/10.2147/OTT.S202867
work_keys_str_mv AT starrjasons peptidereceptorradionuclidetherapyforthetreatmentofpancreaticneuroendocrinetumorsrecentinsights
AT sonbolmohamadbassam peptidereceptorradionuclidetherapyforthetreatmentofpancreaticneuroendocrinetumorsrecentinsights
AT hobdaytimothyj peptidereceptorradionuclidetherapyforthetreatmentofpancreaticneuroendocrinetumorsrecentinsights
AT sharmaakash peptidereceptorradionuclidetherapyforthetreatmentofpancreaticneuroendocrinetumorsrecentinsights
AT kendiaysetuba peptidereceptorradionuclidetherapyforthetreatmentofpancreaticneuroendocrinetumorsrecentinsights
AT halfdanarsonthorvardurr peptidereceptorradionuclidetherapyforthetreatmentofpancreaticneuroendocrinetumorsrecentinsights

Ejemplares similares